You are here: Industry Insights > Mundipharma

News List

Mundipharma and Cidara’s rezafungin gets Orphan Drug Designation in EU pharmaceutical-technology
January 28, 2021
The European Commission (EC) has adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to Mundipharma and Cidara Therapeutics’ rezafungin for treating ...
Mundipharma donates BETADINE® products to hospitals in Philippines, Thailand and Vietnam to support the fight against COVID-19 prnasia
April 07, 2020
Mundipharma has donated supplies of its BETADINE® range of products to hospitals in Philippines, Thailand and Vietnam to support the efforts of healthcare professionals amidst the outbreak.
Cidara and Mundipharma sign rezafungin drug development deal pharmaceutical-technology
September 05, 2019
US-based biotech Cidara Therapeutics has partnered with UK-based Mundipharma in a deal valued at more than $568m to develop and commercialise its anti-fungal drug rezafungin.
Mundipharma, Cidara ink $568M deal for antifungal treatment biospectrumasia
September 04, 2019
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need
Novartis, Mundipharma ink partnership to enhance access to three Asian countries to established medicine brands for glaucoma and external eye diseases prnasia
August 06, 2019
International healthcare organizations, Novartis and Mundipharma, have signed a landmark agreement for the marketing, sales and distribution rights of Novartis medicines in
Novartis, Mundipharma to enhance access of ophthalmology drugs biospectrumasia
July 28, 2019
To market, sell and distribute Novartis medicines in the general ophthalmology disease area
Mundipharma Acquires Rights to Orexo's Zubsolv contractpharma
July 11, 2019
To commercialize the opioid dependence drug in Australia and New Zealand.
Egis Pharmaceuticals to launch Mundipharma’s Pelmeg in CEE markets pharmaceutical-technology
June 19, 2019
Mundipharma has signed an exclusive distribution agreement that will see Egis Pharmaceuticals introduce its Pelmeg drug in four Central and Eastern Europe (CEE) markets.
Mundipharma’s Neulasta biosimilar approved in EU pharmaphorum
March 07, 2019
A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.
Mundipharma Launches Pelmeg Biosimilar in Europe americanpharmaceuticalreview
February 19, 2019
The Mundipharma network of independent associated companies announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Neulasta following European Commission (EC) approval in November 2018.....

Previous page 1 2 3 4 5 6 Next page